(Sharecast News) - SkinBioTherapeutics said in an update on Thursday that revenue for the year ended 30 June were expected to rise almost fourfold to between £4.5m and £4.8m, driven by a full-year contribution from Dermatonics, eight months from Bio-Tech Solutions (BTS), and continued organic growth in AxisBiotix sales.
The AIM-traded...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE